Literature DB >> 17153907

Primary carcinoid tumors of the lung: a role for radiotherapy.

Heath B Mackley1, Gregory M M Videtic.   

Abstract

Primary neuroendocrine neoplasms of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to the highly aggressive small-cell lung carcinoma. The rarity of carcinoids has made the role of radiation therapy in their management controversial. This review considers the results of published studies to generate treatment recommendations and identify areas for future research. Surgery remains the standard of care for medically operable disease. Histology plays the most important role in determining the role of adjuvant radiation. Resected typical carcinoids likely do not require adjuvant therapy irrespective of nodal statius. Resected atypical carcinoids and large-cell neuroendocrine carcinomas have a significant risk of localfailure, for which adjuvant radiation likely improves local control. Definitive radiation is warranted in unresectable disease. Palliative radiation for symptomatic lesions has demonstrated efficacy for all histologies. Collaborative group trials are warranted.

Entities:  

Mesh:

Year:  2006        PMID: 17153907

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  9 in total

1.  Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience.

Authors:  Ryan F Herde; Kristine E Kokeny; Chakravarthy B Reddy; Wallace L Akerley; Nan Hu; Jonathan P Boltax; Ying J Hitchcock
Journal:  Am J Clin Oncol       Date:  2018-01       Impact factor: 2.339

2.  Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.

Authors:  Yusuf Menda; M Sue O'Dorisio; Simon Kao; Geetika Khanna; Stacy Michael; Mary Connolly; John Babich; Thomas O'Dorisio; David Bushnell; Mark Madsen
Journal:  J Nucl Med       Date:  2010-09-16       Impact factor: 10.057

Review 3.  The Diagnosis and Treatment of Bronchopulmonary Carcinoid.

Authors:  Jussuf T Kaifi; Gian Kayser; Juri Ruf; Bernward Passlick
Journal:  Dtsch Arztebl Int       Date:  2015-07-06       Impact factor: 5.594

4.  Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors.

Authors:  Kevin L Anderson; Michael S Mulvihill; Paul J Speicher; Babatunde A Yerokun; Brian C Gulack; Daniel P Nussbaum; David H Harpole; Thomas A D'Amico; Mark F Berry; Matthew G Hartwig
Journal:  Ann Thorac Surg       Date:  2017-07-29       Impact factor: 4.330

5.  Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors.

Authors:  Robert Fred Henry Walter; Claudia Vollbrecht; Daniel Christoph; Robert Werner; Jan Schmeller; Elena Flom; Georgia Trakada; Aggeliki Rapti; Vasilis Adamidis; Wolfgang Hohenforst-Schmidt; Jens Kollmeier; Thomas Mairinger; Jeremias Wohlschlaeger; Paul Zarogoulidis; Konstantinos Porpodis; Kurt Werner Schmidt; Fabian Dominik Mairinger
Journal:  J Cancer       Date:  2016-10-25       Impact factor: 4.207

6.  Carcinoid Tumor Arising from the Sphenoid Sinus Treated with Definitive Intensity-modulated Radiation Therapy: A Case Report.

Authors:  Lara Hilal; Mustafa Jammal; Ibrahim Khalifeh; Arafat Tfayli; Bassem Youssef
Journal:  Cureus       Date:  2019-03-21

7.  Stereotactic body radiation therapy versus fractionated radiation therapy for early-stage bronchopulmonary carcinoid.

Authors:  Rodney E Wegner; Stephen Abel; Zachary D Horne; Shaakir Hasan; Athanasios Colonias; Vivek Verma
Journal:  Lung Cancer Manag       Date:  2019-08-21

Review 8.  The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung.

Authors:  Mateusz Bilski; Paulina Mertowska; Sebastian Mertowski; Marcin Sawicki; Anna Hymos; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

9.  Outcomes after surgical resection of pulmonary carcinoid tumors.

Authors:  Ikenna C Okereke; Angela M Taber; Rogers C Griffith; Thomas T Ng
Journal:  J Cardiothorac Surg       Date:  2016-03-02       Impact factor: 1.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.